In this issue of JAMA Internal Medicine, Bruch and colleagues1 inform us that during the past decade, private equity firms have acquired or invested in large numbers of obstetrician-gynecologist medical groups. Most of these acquisitions and investments occurred during the past 3 years. Given the difficulty of identifying such acquisitions and investments, it is likely that their true number is even larger than Bruch and colleagues report, despite the labor-intensive methods the authors employed to identify them.
Identify all potential conflicts of interest that might be relevant to your comment.
Conflicts of interest comprise financial interests, activities, and relationships within the past 3 years including but not limited to employment, affiliation, grants or funding, consultancies, honoraria or payment, speaker's bureaus, stock ownership or options, expert testimony, royalties, donation of medical equipment, or patents planned, pending, or issued.
Err on the side of full disclosure.
If you have no conflicts of interest, check "No potential conflicts of interest" in the box below. The information will be posted with your response.
Not all submitted comments are published. Please see our commenting policy for details.
Casalino LP. Private Equity, Women’s Health, and the Corporate Transformation of American Medicine. JAMA Intern Med. 2020;180(11):1545–1546. doi:10.1001/jamainternmed.2020.3564
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: